Skip to main content

Advertisement

Log in

Reliability of S100B in predicting severity of central nervous system injury

Neurocritical Care Aims and scope Submit manuscript

Abstract

S100B is a protein biomarker that reflects CNS injury. It can be measured in the CSF or serum with readily available immunoassay kits. The excellent sensitivity of S100B has enabled it to confirm the existence of subtle brain injury in patients with mild head trauma, strokes, and after successful resuscitation from cardiopulmonary arrest. The extent of S100B elevation has been found to be useful in predicting clinical outcome after brain injury. Elevations of S100B above certain threshold levels might be able to reliably predict brain death or mortality. A normal S100B level reliably predicts the absence of significant CNS injury. The specificity of S100B levels as a reflection of CNS injury is compromised by the findings that extra-cranial injuries can lead to elevations in the absence of brain injury. This potential problem can most likely be avoided by measuring serial S100B levels along with other biomarkers and carefully noting peripheral injuries. Serum markers GFAP and NSE are both more specific for CNS injury and have little to no extra-cranial sources. Sustained elevations of S100B over 24 h along with elevations of GFAP and NSE can more reliably predict the extent of brain injury and clinical outcomes. In the future, S100B measurements might reliably predict secondary brain injury and enable physicians to initiate therapeutic interventions in a timelier manner. S100B levels have been shown to rise hours to days before changes in ICP, neurological examinations, and neuroimaging tests. S100B levels may also be used to monitor the efficacy of treatments.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Signorini D, Andrews P, Jones P, et al. Predicting survival using simple clinical variables: a case study in traumatic brain injury. J Neurol Neursurg Psychiatry 1999;66:20–5.

    CAS  Google Scholar 

  2. Bakay R, Ward A. Enzymatic changes in serum and Cerebrospinal fluid in neurological injury. J Neurosurgery 1983;58:27–37.

    CAS  Google Scholar 

  3. Bakay R, Sweeney K, Wood J. Pathophysiology of cerebrospinal fluid in head injury: part 2. Biochemical markers for central nervous system trauma. Neurosurgery 1986;18:376–382.

    Article  PubMed  CAS  Google Scholar 

  4. Hans P, Born J, Chapelle J, et al. Creatine kinase isoenzymes in severe head injury. J Neurosurg 1983;58:689–92.

    PubMed  CAS  Google Scholar 

  5. Kossmann T, Stahel P, Lenzlinger P, et al. Interleukin-8 released into the cerebrospinal fluid after brain injury is associated with blood brain barrier dysfunction and nerve growth factor production. J Cereb Blood Flow Metab 1997;17:280–9.

    PubMed  CAS  Google Scholar 

  6. Bell M, Kochanek P, Hayes M, et al. Quinolinic acid in the cerebrospinal fluid of children after traumatic brain injury. Crit Care Med 1999;27:493–7.

    PubMed  CAS  Google Scholar 

  7. Hans P, Born J, Albert A. “Extrapolated” creatine kinase-BB isoenzyme activity in assessment of initial brain damage after severe head injury. J Neurosurg 1987;66:714–7.

    PubMed  CAS  Google Scholar 

  8. Morganti-Kossmann M, Hans V, Lenzlinger P, et al. TGF-beta is elevated in the SCF of patients with severe traumatic brain injuries and parallels blood-brain barrier function. J Neurotrauma 1999;16:617–28.

    PubMed  CAS  Google Scholar 

  9. Rao C, Shukla P, Mohanty S, et al. Predictive value of serum lactate dehydrogenase in head injury. J Neurol Neurosurg Psychiatry 1978;41:948–53.

    PubMed  CAS  Google Scholar 

  10. Thomas D, Palfreyman J, Ratcliffe J. Serum-myelin-basic-protein assay in diagnosis and prognosis of patients with head injury. Lancet 1978;1:113–5.

    PubMed  CAS  Google Scholar 

  11. Ikeda Y, Hayashi M, Dohi K, et al. Biochemical markers for brain damage. Neurosurg Quart 2001;11:173–80.

    Google Scholar 

  12. Kligman D, Hilt D. The S100 protein family. Trends Biochem Sci 1988;13:437–43.

    PubMed  CAS  Google Scholar 

  13. Ishiguro Y, Kato K, Ito T, Nagaya M. Determination of three enolase isoenzymes and S100 protein in various tumors in children. Cancer Res 1983;43:6080–4.

    PubMed  CAS  Google Scholar 

  14. Hayashi K, Hoshida Y, Horie Y, et al. Immunohistochemical study on the distribution of alpha and beta subunits of S-100 protein in brain tumors. Acta Neuropathol (Berl) 1991;81:657–63.

    CAS  Google Scholar 

  15. Hachitand Y, Nakagawara A, Negoshi M, et al. Prognostic value of N-myc oncogene amplicfication and S-100 protein positivity in children with neuroblastic tumors. Acta Pathol Jpn 1992;42:639–44.

    Google Scholar 

  16. Donato R. S100: A multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol 2001;33:637–68.

    PubMed  CAS  Google Scholar 

  17. Donato R. Functional roles of S100 proteins, calcium-binding proteins of the EF-hand type. Biochimica et Biophysica Acta 1989;35:191–231.

    Google Scholar 

  18. Isobe T, Takahashi K, Okuyama T. S100aO (alpha alpha) protein is present in neurons of the central and peripheral nervous system. J Neurochem 1984;43:1494–6.

    PubMed  CAS  Google Scholar 

  19. Heizmann C. Ca2 + -binding S100 proteins in the central nervous system. Neurochem Res 1999;24:1097–100.

    PubMed  CAS  Google Scholar 

  20. Schafer B, Heizmann C. The S100 family of ER-hand calcium-binding proteins: functions and pathology. Trends Biochem Sci 1996;21:134–40.

    PubMed  CAS  Google Scholar 

  21. Fano G, Biocca S, Fulle S, et al. The S-100: a protein family in search of a function. Progress Neurobiol 1995;46:71–82.

    CAS  Google Scholar 

  22. Zimmer D, Cornwall E, Landar A, et al. The S100 protein family: history, function, and expression. Brain Res Bull 1995;37:417–29.

    PubMed  CAS  Google Scholar 

  23. JensenR, Marshak D, Anderson, et al. Characterization of human brain S100 protein fraction: amino acid sequence of S100 beta. J Neurochem 1985;45:700–5.

    Google Scholar 

  24. Stefansson K, Wollmann R, Jerkovic M. S-100 protein in soft tissue tumors derived from Schwann cells and melanocytes. Am J Pathol 1982;106:261–8.

    PubMed  CAS  Google Scholar 

  25. Hidaka H, Enso T, Kawamoto M, et al. Purification and characterization of adipose tissue S-100b protein. J Biol Chem 1985;258:2705–9.

    Google Scholar 

  26. Stefansson K, Wollmann R, Moore B, et al. S-100 protein in human chondrocytes. Nature (London) 1982;295:63–4.

    CAS  Google Scholar 

  27. Nakjima T, Sato Y, Watanabe S, et al. Immunoelctron microscopical demonstration of S-100 protein in epidermal Langerhans cells. Biomed Res 1982;8:226–31.

    Google Scholar 

  28. Shasboua V, Hesse G, Moore B. Proteins of the brain extracellular fluid: evidence for release of S-100 protein. J Neurochem 1984;42:1536–41.

    Google Scholar 

  29. Eng L, Ghirnikar R. GFAP and astrogliosis. Brain Pathol 1994;4:229–37.

    PubMed  CAS  Google Scholar 

  30. Barger S, Van Eldik L. S100 beta stimulates calcium fluxes in glial and neuronal cells. J Biol Chem 1992;267:9689–94.

    PubMed  CAS  Google Scholar 

  31. Selinfreund R, Barger S, Pledger W, et al. Neurotrophic protein S100 beta stimulates glial cell proliferation. Proc Natl Acad Sci USA 1991;88:3554–3508.

    PubMed  CAS  Google Scholar 

  32. Scotto C, Deloulme J, Rousseau D, et al. Calcium and S100B regulation of p53-dependent cell growth arrest and apoptosis. Mol Cell Biol 1998;18:4272–81.

    PubMed  CAS  Google Scholar 

  33. Baudier J, Delphin C, Grunwald D, et al. Characterization of the tumor suppressor protein p53 as a protein kinase c substrate and a S100B-binding protein. Proc Natl Acad Sci USA 1992;89:11627–31.

    PubMed  CAS  Google Scholar 

  34. Whitaker-Azmitia P, Murphy R, Azmitia E. Stimulation of astroglial 5-HT1A receptors releases the serotonergic growth factor, protein S-100, and alters astroglial morphology. Brain Res 1990;528:155–8.

    PubMed  CAS  Google Scholar 

  35. Suzuki F, Kato K, Kato T, et al. S-100 protein in clonal astroglioma cells is released by adrenocorticotropic hormone and corticotropin-like intermediate-lobe peptide. J Neurchem 1987;49:1557–63.

    CAS  Google Scholar 

  36. Ciccarelli R, Di Iorio P, Bruno V, et al. Activation of A(1) adenosine or mGlu3 metabotropic glutamate receptors enhances the release of nerve growth factor and S-100 beta protein from cultured astrocytes. Glia 1999;27:275–81.

    PubMed  CAS  Google Scholar 

  37. Headrick J, Bendall M, Faden A, et al. Dissociation of adenosine levels from bioenergetic state in experimental brain trauma: potential role in secondary injury. J Cereb Blood Flow Metab 1994;14:853–61.

    PubMed  CAS  Google Scholar 

  38. Nilsson P, Hillered L, Ponten U, et al. Changes in cortical extracellular levels of energy-related metatbolites and amino acides following concussive brain injury in rats. Cereb Blood Flow Metab 1990;10:631–7.

    CAS  Google Scholar 

  39. Rudolphi K, Schubert P, Parkinson F, et al. Adenosine and brain ischemia. Cerebrovasc Brain Metab Rev 1992;4:346–69.

    PubMed  CAS  Google Scholar 

  40. Marshak D. S-100 beta as a neurotrphic factor. Prog Brain Res 1990;86:169–81.

    Article  PubMed  CAS  Google Scholar 

  41. Janeczko K. The proliferative response of S-100 protein-positive glial cells to injury in the neonatal rat brain. Brain Res 1991;564(1):86–90.

    PubMed  CAS  Google Scholar 

  42. Takana H, Akari M, Masuzawa T. Reaction of astrocytes in gerbil hippocampus following transient ischemia: Immunohistochemical observations with antibodies against glial fibrillary acidic protein, gluatime synthesase and S-100 protein. Exp Neurol 1992;116:264–74.

    Google Scholar 

  43. Petzold A, Keir G, Lim D, et al. CSF and serum S100B: Release and wash-out pattern. Brain Res Bull 2003;15,61(3):281–5.

    Google Scholar 

  44. Jonsson H, Johnsson P, Hoglund P, et al. Elimination of S100B and renal function after cardiac surgery. J Cardiothras Vasc Anesth 2000;6:698–701.

    Google Scholar 

  45. Beaudeux L, Leger P, Dequen P, et al. Influence of hemolysis on the measurement of S-100B protein and neuron-specific enolase plasma concentrations during coronary artery bypass grafting. Clin Chem 2000;46:989–90.

    PubMed  CAS  Google Scholar 

  46. Nygaard Y, Langhakk B, Romner B. Age and sex related changes of S100B protein concentrations in cerebrospinal fluid and serum in patients with no previous history of neurological disorder. Clin Chem 1997;43:541–7.

    PubMed  CAS  Google Scholar 

  47. Wiesmann M, Missler U, Grottmann D, et al. Plasma S100B protein concentration in healthy adults is age and sex independent. Clin Chem 1998;44:1056–7.

    PubMed  CAS  Google Scholar 

  48. Takahashi M, Chamezuk A, Hong Y, et al. Rapid and sensitive immunoassay for the measurement of serum S100B using isoform-specific monoclonal antibody. Clin Chem 1999;45:1307–11.

    PubMed  CAS  Google Scholar 

  49. Ettinger A, Laumark A, Ostroff R, et al. A new optical immunoassay for detection of S100 protein in whole blood. Ann Thorac Surg 1999;68:2196–201.

    PubMed  CAS  Google Scholar 

  50. Xu W, Xie F, Lei E, et al. Construction and clinical application of ELISA in detecting serum protein S100B. Shanghai J Immunol 2002;22:119–120.

    Google Scholar 

  51. Chen D, Ziiu L. Dynamic change of serum protein S100B and its clinical significance in patients with traumatic brain injury. Chin J Traumatol 2005;8(4):245–8.

    PubMed  CAS  Google Scholar 

  52. Smit L. Four different assays for the determination of serum S-100 B compared. Int J Biol Marker 2005;20(1):34–42.

    CAS  Google Scholar 

  53. Harpio R, Einarsson R. S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma. Clin Biochem 2004;37(7):512–8.

    PubMed  CAS  Google Scholar 

  54. Alber B, Hein R, Garbe C, et al. Multicenter evaluation of the analytical and clinical performance of the Elecsys S100 immunoassay in patients with malignant melanoma. Clin Chem Lab Med 2005;43(5):557–63.

    PubMed  CAS  Google Scholar 

  55. Musack T, Klauss V, Ruppert V, et al. Rapid measurement of S-100B serum protein levels by Elecsys S100 immunoassay in patients undergoing carotid artery stenting or endarterectomy. Clin Biochem 2006;39(4):349–356.

    Google Scholar 

  56. Poli-de-Fiqueiredo L, Biberthaler P, Filho C, et al. Measurement of S-100B for risk classification of victims sustaining minor head injury – first pilot study in Brazil. Clinics 2006;61.

  57. Lins H, Wallesch C, Wunderlich M. Sequential analyses of neurobiochemical markers of cerebral damage in cerebrospinal fluid and serum in CNS infections. Acta Neurologica Scandinavica 2005;112:303–8.

    PubMed  CAS  Google Scholar 

  58. Heizmann C. S100B Protein in Clinical Diagnostics: Assay Specificity. Clin Chem 2004;50:249–51.

    PubMed  CAS  Google Scholar 

  59. Raabe A, Menon D, Gupta S, et al. Jugular and arterial concentrations of serum S100B protein in patients with severe head injury: a pilot study. J Neurol Neurosurg Psychiatry 1998;65:930–2.

    PubMed  CAS  Google Scholar 

  60. McKeating E, Andrews P, Mascia L, et al. Relationship of neuron specific enolase and S100 concentrations in systemic and jugular venous serum to injury severity and outcome after traumatic brain injury. Acta Neurochir Suppl (Wein) 1998;71:117–9.

    CAS  Google Scholar 

  61. Bakay R, Sweeney K, Wood J. Pathophysiology of cerebrospinal fluid in head injury: part 2. Biochemical markers for central nervous system trauma. Neurosurgery 1986;18:376–82.

    Article  PubMed  CAS  Google Scholar 

  62. Berger R, Pierce M, Wisniewski S, et al. Neuron-specific enolase and S100B in cerebrospinal fluid after severe traumatic brain injury in infants and children. Pediatrics 2002;109:E31.

    PubMed  Google Scholar 

  63. Kruse A, Cesarini K, Bach F, et al. Increases of neuron-specific enolase, S-100 protein, creatine kinase and creatine kinase BB soenzyme in CSF following intraventricular catheter implantation. Acta Neurochir 1991;110:106–9.

    CAS  Google Scholar 

  64. Nygaard O, Langbakk B, Romner B. Age and Sex related changes in S100 protein concentrations in the cerebrospinal fluid and serum in patients with no previous history of neurological injury. Clin Chem 1997;43:541–3.

    PubMed  CAS  Google Scholar 

  65. Wiesmann M, Missler U, Gottmann D, et al. Plasma S100B protein concentrations in healthy adults is age and sex-independent. Clin Chem 1998;44:1056–8.

    PubMed  CAS  Google Scholar 

  66. Anderson R, Hansson L-O, Nilsson O, et al. High serum S100 levels for trauma patients without head injury. Neurosurgery 2001;48:1255–8.

    PubMed  CAS  Google Scholar 

  67. Ingebrigtsen T, Romner B Marup-Jensen S, et al. The clinical value of serum S-100 protein measurement in minor head injury; a Scandinavian multicentre study. Brain Inj 2000;14:1047–55.

    PubMed  CAS  Google Scholar 

  68. Ingebritsen T, Romner B, Kongstad P, et al. Increased serum concentrations of protein S-100 after minor head injury: a biochemical serum marker with prognostic value? J Neurol Neurosurg Psychiatry 1995;59:103–4.

    Google Scholar 

  69. Hermann M, Curio N, Jost S, et al. Protein S-100B and neuron specific enolase as early neurobiochemical markers of the severeity of traumatic brain injury. Restor Neurol Neurosci 1999;14:109–14.

    Google Scholar 

  70. Vos P, Lamers K, Hendriks J, et al. Glial and neuronal proteins in serum predict outcome after severe traumatic brain injury. Neurology 62:1303–10.

  71. Rothoerl R, Woertgen C, Holzschub M, et al. S-100 serum levels after minor and major head injury. J Trauma 1998;45:765–7.

    PubMed  CAS  Google Scholar 

  72. Savola O, Pyhtinen J, Leino T, et al. Effects of Head and Extra-cranial Injuries on Serum Protein S100B Levels in Trauma Patients. J Trauma Injury, Infection, Critical Care 2004;56(6):1229–34.

    CAS  Google Scholar 

  73. Romner B, Ingebrigtsen T, Kongstad P, et al. Traumatic brain damage: serum S-100 protein measurements related to neuroradiological findings. J Neurotrauma 2000;8:641–7.

    Google Scholar 

  74. Townend W, Guy M, Pani M, et al. Head injury outcome prediction in the emergency department: a role for protein S-100B? J Neurol Neurosurg Psychiatgry 2002;73:542–6.

    CAS  Google Scholar 

  75. Hermann M, Jost S, Kutz S, et al. Temporal profile of release of neurobiochemical markers of brain damage after traumatic brain injury is associated with intracranial pathology as demonstrated in cranial computerized tomography. J Neurotrauma 2000;17:113–22.

    Google Scholar 

  76. Herrmann M, Vos P, Wunderlich M, et al. Release of glial specific tissue proteins after an acute stroke: a comparative analysis of serum concentrations of protein S100B and glial fibrillary acidic protein. Stroke 2000;31:2670–7.

    PubMed  CAS  Google Scholar 

  77. Beems T, Simms K, van Geel W, et al. Serum and CSF concentrations of brain specific proteins in hydrocephalus. Acta Neurochir (Wein) 2003;145:37–43.

    CAS  Google Scholar 

  78. Weismann M, Missler U, Hagenstrom H, et al. S-100 protein plasma levels after aneurismal subarachnoid haemorrhage. Acta Neurochir 1997;139:1155–60.

    Google Scholar 

  79. Lins H, Wallesch C, Wunderlich M. Sequential analyses of neurobiochemical markers of cerebral damage in cerebrospinal fluid and serum in CNS infections. Acta Neurologica Scandinavica 1125:303–8.

  80. Kato K, Kimura S. S100aO (alpha alpha) protein is mainly located in the heart and striated muscles. Biochim Biophys Acta 1985;842:146–50.

    PubMed  CAS  Google Scholar 

  81. Haimoto H, Hosoda S, Kato K. Differential distribution of immunoreactive S100-alpha and S100-beta proteins in normal non-nervous human tissues. Lab Invest 1987;57:489–98.

    PubMed  CAS  Google Scholar 

  82. Otto M, Holthusen S, Bahn E, et al. Boxing and running lead to elevated serum levels of S-100B protein. Int J Sports Med 2000;21:551–5.

    PubMed  CAS  Google Scholar 

  83. Stalnacke B, Tegner Y, Sojka P. Playing ice hockey and basketball increases serum levels of S-100B in elite players: a pilot study. J Sport Med 2003;13:292–302.

    Google Scholar 

  84. Hasselblatt M, Mooren F, von Ahsen N, et al. Serum S100B increases in marathon runners reflect extracranial release rather than glal damage. Neurology 2004;62:1634–6.

    PubMed  CAS  Google Scholar 

  85. Romner B, Ingebrigtsen T. High serum S100B levels in trauma patients without head injury. Neurosurgery 2001;41:1490–3.

    Google Scholar 

  86. Schmidt B, Bauersfeld U, Schmid E, et al. Serum and CSF levels of neuron specific enolase NSE in cardiac surgery with cardiopulmonary bypass: a marker of brain injury? Brain Dev 1998;20:536–9.

    Google Scholar 

  87. Eng L. Glial fibrillary acidic protein (GFAP): the major protein of intermediate filaments in differentiated astrocytes. J Neuroimmuna 1985;8:203–14.

    CAS  Google Scholar 

  88. Missler U, Wiesmann M, Friedrich C, et al. S-100 protein and neuron-specific enolase concentrations in blood as indicators of infarction volume and prognosis in acute ischemic stroke. Stroke 1997;28:1956–60.

    PubMed  CAS  Google Scholar 

  89. Buttner T, Weyers S, Postert T, et al. S-100 protein: Serum marker of focal brain damage after ischemic tgerritorial MCA infarction. Stroke 1997;28:1961–5.

    PubMed  CAS  Google Scholar 

  90. Abraha H, Butterworth R, Bath P, et al. Serum S-100 protein, relationship to clinical outcome in acute stroke. Ann Clin Biochem 1997;34:366–70.

    PubMed  Google Scholar 

  91. Fassbender K Schmidt R, Schreiner A, et al. Leakage of brain-originated proteins in peripheral blood: Temporal profile and diagnostic value in early ischemic stroke. J Neurol Sci 1997;148:101–5.

    Google Scholar 

  92. Persson L, Hardemark H, Gustafsson J, et al. S-100 protein and neuron-specific enolase in cerebrospinal fluid and serum: markers of cell damage in human central nervous system. Stroke 1987;18:911–8.

    PubMed  CAS  Google Scholar 

  93. Elting J, de Jager A, Teelken A, et al. Comparison of serum S-100 protein levels following stroke and traumatic brain injury. J Neurol Sci 2000;181:104–10.

    PubMed  CAS  Google Scholar 

  94. Connolly E, Winfree C, Rampersad A, et al. Serum S100B protein levels are correlated with subclinical neurocognitive declines after carotid endarterectomy. Neurosurgery 2001;49:1067–82.

    Google Scholar 

  95. Takana H, Akari M, Masuzawa T. Reaction of astrocytes in gerbil hippocampus following transient ischemia: Immunohistochemical observations with antibodies against glial fibrillary acidic protein, gluatime synthesase and S-100 protein. Exp Neuroolgy 1992;116:264–74.

    Google Scholar 

  96. Smidt-Kastner R, Szymas J, Hossmann K. Immunohistochemical study of glial reaction and serum-protien extravasation in relation to neuronal damage in rat hippocampus after ischemia. Neuroscience 1990;38:527–40.

    Google Scholar 

  97. Postler E, Lehr A, Schluescner H, Meyermann R. Expression of S-100 proteins MRP-8 and -14 in ischemic brain lesions. Glia 1997;19:27–34.

    PubMed  CAS  Google Scholar 

  98. Wundedrlich M, Wallesch C, Goertler M. Release of neurobiochemical markers of brain damage is related to the neurovascular status on admission and the site of arterial occlusion in acute ischemic stroke. J Neurol Sci 2004;227:49–53.

    Google Scholar 

  99. Rosen H, Rosengren L, Herlitz J, Blomstrand C. Increased serum levels of the S-100 protein are associated with hypoxic brain damage after cardiac arrest. Stroke 1998;29:473–7.

    PubMed  CAS  Google Scholar 

  100. Wong C, Rooney S, Bonser R. S-100B release in hyothermic circulatory arrest and coronary artery surgery. Ann Thorac Surg 1999;67:1911–4.

    PubMed  CAS  Google Scholar 

  101. Kilminster S, Treasure T, McMillian T, Holt D. Neuropsychological change and S-100 protein release in 130 unselected patients undergoing cardiac surgery. Stroke 1999;30:1869–74.

    PubMed  CAS  Google Scholar 

  102. Bates D. The management of medical coma. J Neurol Neurosurg Psychiatry 1993;56:589–98.

    PubMed  CAS  Google Scholar 

  103. Martens P, Raabe A, Hohnsson P. Serum S-100 and neuro-specific enolase for prediction of regaining consciouness after global cerebral ischemia. Stroke 1998;29:2363–6.

    PubMed  CAS  Google Scholar 

  104. Hachimi-Idrissi S, Van der Auwere M, Schiettecatte J, et al. S-100 protein as early predictor of regaining consciousness after out of hospital cardiac arrest. Resuscitation. 2002;53:251–7.

    PubMed  CAS  Google Scholar 

  105. Hachimi-Idrissi S, Zizi M, Nguyen D, et al. The evolution of serum astroglial S-100 beta protein with cardiac arrest treated with mild hypothermia. Resuscitation. 2005;64:187–92.

    PubMed  CAS  Google Scholar 

  106. Ingebrigtsen T, Waterloo K, Jacobsen E, et al. Traumatic Brain Damage in Minor Head Injury: Relation of Serum S-100 Protein Measurement to Magnetic Resonance Imaging and Neurobehavioral Outcome. Neurosurgery 1999;45(3):468–76.

    PubMed  CAS  Google Scholar 

  107. Raabe A, Grolms C, Seifert V. Serum markers of brain damage and outcome prediction in patients after severe head injury. J␣Neurosurg 1999;13:56–9.

    CAS  Google Scholar 

  108. Herrman M, Curio N, Jost S, et al. Release of biochemical markers of damage to neuronal and glial brain tissue is associated with short and long term neuropsychological outcome after traumatic brain injury. J Neurol Neruosurg Psychiatry. 2001;70:95–100.

    Google Scholar 

  109. Waterloo K, Ingebrgitsen T, Romner B. Neuropsychological function in patients with increased serum levels of protein S-100 after minor head injury. Acta Neurochir. 1997;139:26–32.

    CAS  Google Scholar 

  110. Savola O, Hillbom M. Early predictors of post-concussion symptoms in patients with mild head injury. Eur J Neurol. 2003;10:175–181.

    PubMed  CAS  Google Scholar 

  111. Raabe A, Grolms C, Sorge O, et al. Serum S-100B protein in severe head injury. Neurosurgery, 1999;45:477–83.

    PubMed  CAS  Google Scholar 

  112. Raabe A, Grolms C, Keller M. Correlation of computed tomography findings and serum brain damage markers following severe head injury. Acta Neurochir 1998;140:787–92.

    CAS  Google Scholar 

  113. Ghajar J. Traumatic brain injury. Lancet 2000;356:923–9.

    PubMed  CAS  Google Scholar 

  114. Sosin D, Sniezek J, Waxweiler R. Trends in death associated with traumatic brain injury 1979 through 1992. JAMA 1995;273:1778–80.

    PubMed  CAS  Google Scholar 

  115. Teasdale G, Jennet B. Assessment of coma and impaired consciousness. A practical scale. Lancet 1974;13:81–4.

    Google Scholar 

  116. Wardlaw J, Easton V, Statham P. Which CT features help predict outcome after head injury? J Neurol Neurosurg Psychiatry 2002;72:188–92.

    PubMed  CAS  Google Scholar 

  117. Petzold A, Green A, Keir G, et al. Role of serum S100B as an early predictor of high intracranial pressure and mortality in brain injury: A pilot study. Crit Care Med 2002;30(12):2705–10.

    PubMed  CAS  Google Scholar 

  118. Zink B. Traumatic brain injury outcome: Concepts for emergency care. Ann Emerg Med 2001;37:318–32.

    PubMed  CAS  Google Scholar 

  119. Choi S, Barnes T. (1996) Predicting outcome in the head-injured patient. In: Narayan R, Wilberger J, Povlishock J (eds) Neurotrauma, vol 53. McGraw Hill, NYC pp. 779–92.

    Google Scholar 

  120. Dimopoulou I, Korfias S, Dafni U, et al. Protein S-100b serum levels in trauma induced brain death. Neurology 2003;60:947–51.

    PubMed  CAS  Google Scholar 

  121. Woertgen C, Rothoerl R, Holzschuh M, et al. Comparison of serial S100 and NSE serum measurements after severe head injury. Acta Neurochir (Wein) 1997;139:1161–4.

    CAS  Google Scholar 

  122. Rothoerl R, Woertgen C, Brawanski A. S-100 serum levels and outcome after severe head injury. Acta Neurochir Suppl 2000;76:97–100.

    PubMed  CAS  Google Scholar 

  123. McKeating E, Andrews P, Mascia L. Relationship of neuron specific enolase and S100 concentrations in systemic and jugular venous serum to injury severity and outcome after traumatic brain injury. Acta Neurochir Suppl (Wein) 1998;71:117–9.

    CAS  Google Scholar 

  124. Woertgen C, Rothoerl R, Metz C, et al. A comparison of clinical, radiologic and serum marker of prognostic factors after severe head injury. J Trauma 1999;47:1126–1130.

    PubMed  CAS  Google Scholar 

  125. Pleines U, Morganti-Kossmann M, Rancan M, et al. S100B reflects the injury and outcome, whereas neuronal specific enolase is a better indicator of neuroinflammation in patients with severe traumatic brain injury. J Neurotrauma 2001;18:491–98.

    PubMed  CAS  Google Scholar 

  126. Pelinka L, Toegel E, Mauritz W, et al Serum S100B: A marker of brain damage in traumatic brain injury with and without multiple trauma. Shock 2003;19:195–200.

    PubMed  CAS  Google Scholar 

  127. Wijdicks E. The diagnosis of brain death. N Engl J Med 2001;344:1215–21.

    PubMed  CAS  Google Scholar 

  128. Wijdicks E. Brain death worldwide: accepted fact but no global consensus in diagnostic criteria. Neurology 2002;58:20–5.

    PubMed  Google Scholar 

  129. Miller J, Becker D, Ward J, et al. Significance of intracranial hypertension in severe head injury. J Neurosurg 1977;47:503–16.

    PubMed  CAS  Google Scholar 

  130. Regner A, Kaufman M, Friedman G, et al. Increased serum S100B protein concentrations following severe head injury in humans: a biochemical marker for brain death? Neuroreport 2001;12:691–4.

    PubMed  CAS  Google Scholar 

  131. Raabe A, Seifert V. Fatal secondary increase in serum S100B protein after severe head injury. J of Neurosurgery 1999;91:875–7.

    Article  CAS  Google Scholar 

  132. Woertgen C, Rothoerl R, Brawanski A, et al. A time profile of neuron specific enolase serum levels after experimental brain injury in rat. Acta Neurochir suppl 2000;76:371–3.

    PubMed  CAS  Google Scholar 

  133. Jackson R, Samra G, Radcliffe J, et al The early fall in levels of S100 beta in traumatic brain injury. Clin Chem Lab Med 2000;38:1165–7.

    PubMed  CAS  Google Scholar 

  134. Ali M, Harmer M, Vaughan R. Serum S100 protein as a marker of cerebral damage during cardiac surgery. Br J Anaesth 2000;85:287–98.

    PubMed  CAS  Google Scholar 

  135. Graham D, Ford I, Adams J, et al. Ischemic brain damage is still common in fatal non missile head injury. J Neurol Neurosurg Psychiatry 1989;52:346–50.

    PubMed  CAS  Google Scholar 

  136. Schmitt B, Bauersfelf U, Schmid E, et al. Serum and CSF levels of neuron-specific enolase (NSE) in cardiacv surgery with cardiopulmonary bypass: a marker of brain injury? Brain Dev 1998;20:536–9.

    PubMed  CAS  Google Scholar 

  137. Maragos P, Schmechel D. Neuron specific enolase, a clinically useful marker for neurons and neuroendocrine cells. Annu Rev Neurosci 1987;10:269–95.

    Google Scholar 

  138. Gervitz K, Summer J, Schumacher I, et al. Enolase isoenzymes as tumour markers. J Clin Chem Clin Biochem 1986;24:1009–16.

    Google Scholar 

  139. Yamazaki Y, Yada K, Morii S, et al. Diagnostic significance of serum neuron-specific enolase and myelin basic protein assay in patients with acute head injury. Surg Neurol 1995;43:267–70.

    PubMed  CAS  Google Scholar 

  140. Kleine T, Benes L, Zofel P. Studies of the brain specificity of S100B and neuron-specific enolase (NSE) in blood serum of acute care patients. Brain Res Bull 2003;61(3):265–79.

    PubMed  CAS  Google Scholar 

  141. Aurell A, Rosengren L, Karlsson B, et al. Determination of S-100 and glial fibrillary acidic protein concentrations in cerebrospinal fluid after brain infarction. Stroke 1991;22:1254–8.

    PubMed  CAS  Google Scholar 

  142. Tullberg M, Rosengren L, Blomsterwall E, et al. CSF neurofilament and glial fibrillary acidic protein in normal pressure hydrocephalus. Neurology 1998;50:1122–7.

    PubMed  CAS  Google Scholar 

  143. Wallin A, Blennow K, Rosengren L. Glial fibrillary acidic protein in the cerebrospinal fluid of patients with dementia. Dementia 1996;7:267–72.

    PubMed  CAS  Google Scholar 

  144. Hausmann R, Riess R, Fieguth A, et al. Immunohistochemical investigations on the course of astroglail GFAP expression following human brain injury. Int J Legal Med 2000; 113:70–5.

    PubMed  CAS  Google Scholar 

  145. Missler U, Wiesmann M, Wittmann G, et al. Measurement of glial fibrillary acidic protein in human blood: analytical method and preliminary clinical results. Clin Chem 1999;45:138–41.

    PubMed  CAS  Google Scholar 

  146. Van Geel W, de Reus H, Nijzing H, et al. Measurement of glial fibrillary acidic protein in blood: an analytical method. Clin Chim Acta 2002;236:151–4.

    Google Scholar 

  147. Pelinka L, Kroepel A, Leixnering M, et al. GFAP versus S100B in Serum after traumatic brain injury: Relationship to brain damage and outcome. J Neurotrauma 2004;21(11):1553–61.

    PubMed  Google Scholar 

  148. Pelsers M, Hanhoff T, Van der Voort D, et al. Brain and Heart Type Fatty Acid-Binding Proteins in the Brain: Tissue Distribution and Clinical Utility. Clin Chem 2004; 50(9):1568–75.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Stephen M. Bloomfield.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bloomfield, S.M., McKinney, J., Smith, L. et al. Reliability of S100B in predicting severity of central nervous system injury. Neurocrit Care 6, 121–138 (2007). https://doi.org/10.1007/s12028-007-0008-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12028-007-0008-x

Keywords

Navigation